Elena B. Elkin

Featured in: Favicon

jamanetwork.com Favicon

acpjournals.org Favicon

onlinelibrary.wiley.com Favicon

Articles

Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations

Jan 3, 2024 | jamanetwork.com | Victoria Blinder |Mark E. Robson |Elena B. Elkin |Christina M. Zettler

Key PointsQuestion Is adjuvant olaparib cost-effective in patients with early-stage breast cancer with high-risk disease and germline BRCA1/2 mutations?

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →